Keywords: USA, FDA, Novartis, Exjade, Roche, Biogen, Rituxan, Leukemia, CLL

US FDA warns on renal, hepatic and gastro problems with Novartis’ Exjade; clears Roche/Biogen’s Rituxan for CLL

Article | 19 February 2010

Print This

In a web site posting yesterday, the US Food and Drug Administration notified health care professionals about recent changes in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in